Philis-Tsimikas A, et al. - To correlate how glycaemic control might differ between basal insulins at a similar rate of hypoglycaemia, experts designed post hoc analysis of the SWITCH 1 and 2 trials. They examined separate data for HbA1c and symptomatic hypoglycaemia from the SWITCH 1 and SWITCH 2 trials for patients with T1D and T2D, respectively. They evaluated a correlation between the individual patient-level risk of hypoglycaemia and HbA1c applying a Poisson regression model and used to compute potential differences in glycaemic control with degludec vs glargine U100, at the same rate of hypoglycaemia. Results showed that patients in clinical practice may be able to achieve a mean HbA1c reduction of 0.70 (for T1D) or 0.96 (for T2D) percentage points further with degludec than with glargine U100 before incurring an equivalent risk of hypoglycaemia. The outcomes indicated that patients could achieve lower glycaemia targets with degludec vs glargine U100, before incurring an equivalent risk of hypoglycaemia.